Veloxis Pharmaceuticals announced that LCP-Tacro successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002.
The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf as the comparator, met its primary efficacy and primary safety endpoints.
The study was conducted under a Special Protocol Agreement with the FDA and the results are considered pivotal for the planned U.S. regulatory filing expected to occur in the second half of 2013.
"The results observed in this clinical trial suggest that new kidney transplant patients can begin with a regimen of once-daily LCP-Tacro™ rather than twice-daily as required with current tacrolimus products, without compromising efficacy and tolerability," said Dr. Suphamai Bunnapradist, M.D., Professor of Medicine and Director of Kidney Transplant Research at the Ronald Reagan Medical Center and David Geffen School of Medicine at UCLA, California, USA. "This is important because once-daily dosing should be beneficial for kidney transplant patients who are on life-long complex therapy."
LCP-Tacro demonstrated non-inferiority to Prograf in preventing kidney transplant rejection, including in the early post-transplant period
The primary endpoint of the study was a composite endpoint of treatment failure (biopsy-proven acute rejection or BPAR, graft failure, loss to follow up or death) that was evaluated after a 12-month treatment period to demonstrate the non-inferiority of LCP-Tacro compared to Prograf.
The treatment failure rate for LCP-Tacro was 18.3% compared to 19.6% for Prograf, well within the 10% pre-specified non-inferiority margin.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Robot Tongue Identifies The Correct Beer Every Time
- Mystery Of Morgellons - Disease Or Delusion - Scientific Hypothesis Of Connection With Lyme Disease
- Illegal Immigration To The U.S. Caused By Globalization?
- Brain-Computer Interface Makes Communication For Kids With Cerebral Palsy Easier
- Satellites Catch Birth Of Two Volcanic Islands In Yemen
- Editorial Independence Or Extortion? Frontiers Sacks 31 Editors
- Wealthy Elites Will Soon Get GMO-Free Similac
- "Would you please email your email address to me: firstname.lastname@example.org (I think?) I sent..."
- "Okay, they can take Yellow dye #6 out of the nacho cheese, but don't touch mah Cheesy Puffs!..."
- "Jesus H Christ, you have not written a Wikipedia article, you've written the book! I personally..."
- "Thanks, Hank, for taking the time to write your commentary on the issue involving a number of our..."
- "Just found a post by Jester with some more detail on timetables for the rest of the year: http..."
- SanDisk says new SSDs will be price competitive against legacy hard drives
- State regulations for tanning beds not enough: A national regulatory framework is needed
- Hallucinations and delusions more common than thought
- Are antidepressants more effective than assumed?
- Perfume researchers tackle latrines